Quick Answer
Vera Therapeutics, Inc. reported Diluted EPS of $4.66 per share (loss) for fiscal year 2025.
Vera Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.66 | -69.5% |
| 2024 | -$2.75 | -22.2% |
| 2023 | -$2.25 | +32.8% |
| 2022 | -$3.35 | -37.9% |
| 2021 | -$2.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.26 | -48.2% | -5.0% |
| June 30, 2025 | -$1.20 | -93.5% | -48.1% |
| March 31, 2025 | -$0.81 | -44.6% | +4.7% |
| September 30, 2024 | -$0.85 | -88.9% | -37.1% |
| June 30, 2024 | -$0.62 | -34.8% | -10.7% |
| March 31, 2024 | -$0.56 | +30.0% | -24.4% |
| September 30, 2023 | -$0.45 | +50.5% | +2.2% |
| June 30, 2023 | -$0.46 | +16.4% | +42.5% |
- Vera Therapeutics, Inc. showed a decrease of -69.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Vera Therapeutics, Inc.’s diluted eps has declined by 91.8% (from $2.43 per share (loss) to $4.66 per share (loss)).
- The most recent figure is from Vera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: